Engaging African American Men as Citizen Scientists to Validate a Prostate Cancer Biomarker: Work-in-Progress.
Adult
Black or African American
Age Factors
Community Participation
Community-Based Participatory Research
/ organization & administration
Early Detection of Cancer
/ methods
Humans
Male
Middle Aged
Motivation
Patient Selection
Prostate-Specific Antigen
/ blood
Prostatic Neoplasms
/ diagnosis
Social Networking
Socioeconomic Factors
Journal
Progress in community health partnerships : research, education, and action
ISSN: 1557-055X
Titre abrégé: Prog Community Health Partnersh
Pays: United States
ID NLM: 101273946
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
6
8
2019
pubmed:
6
8
2019
medline:
29
8
2020
Statut:
ppublish
Résumé
African American men (AAM) are under-represented in prostate cancer (PCa) research despite known disparities. Screening with prostate-specific antigen (PSA) has low specificity for high-grade PCa leading to PCa over diagnosis. The Prostate Health Index (PHI) has higher specificity for lethal PCa but needs validation in AAM. Engaging AAM as citizen scientists (CSs) may improve participation of AAM in PCa research.Results and Lessons Learned: Eight CSs completed all training modules and 139 AAM were recruited. Challenges included equity in research leadership among multiple principal investigators (PIs) and coordinating CSs trainings. Engaging AAM CSs can support engaging/recruiting AAM in PCa biomarker validation research. Equity among multiple stakeholders can be challenging, but proves beneficial in engaging AAM in research. Assess feasibility of mobilizing CSs to recruit AAM as controls for PHI PCa validation biomarker study. We highlight social networks/assets of stakeholders, CSs curriculum development/implementation, and recruitment of healthy controls for PHI validation.
Sections du résumé
BACKGROUND
African American men (AAM) are under-represented in prostate cancer (PCa) research despite known disparities. Screening with prostate-specific antigen (PSA) has low specificity for high-grade PCa leading to PCa over diagnosis. The Prostate Health Index (PHI) has higher specificity for lethal PCa but needs validation in AAM. Engaging AAM as citizen scientists (CSs) may improve participation of AAM in PCa research.Results and Lessons Learned: Eight CSs completed all training modules and 139 AAM were recruited. Challenges included equity in research leadership among multiple principal investigators (PIs) and coordinating CSs trainings.
CONCLUSIONS
Engaging AAM CSs can support engaging/recruiting AAM in PCa biomarker validation research. Equity among multiple stakeholders can be challenging, but proves beneficial in engaging AAM in research.
OBJECTIVES
Assess feasibility of mobilizing CSs to recruit AAM as controls for PHI PCa validation biomarker study.
METHODS
We highlight social networks/assets of stakeholders, CSs curriculum development/implementation, and recruitment of healthy controls for PHI validation.
Identifiants
pubmed: 31378740
pii: S1557055X19500146
doi: 10.1353/cpr.2019.0043
pmc: PMC6693518
mid: NIHMS1045039
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
103-112Subventions
Organisme : NIMHD NIH HHS
ID : U54 MD012523
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA202995
Pays : United States
Organisme : NIMHD NIH HHS
ID : R01 MD014839
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA202997
Pays : United States
Organisme : NCI NIH HHS
ID : P20 CA202908
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA203000
Pays : United States
Références
Am J Public Health. 2006 Dec;96(12):2093-7
pubmed: 17077406
J Urol. 2007 Feb;177(2):444-9
pubmed: 17222606
Health Serv Res. 2009 Dec;44(6):2093-105
pubmed: 19732170
Hum Genet. 2012 Jan;131(1):41-56
pubmed: 21698460
Health Serv Res. 2012 Jun;47(3 Pt 2):1363-86
pubmed: 22353031
World J Urol. 2014 Feb;32(1):185-91
pubmed: 22527674
Urol Oncol. 2013 Nov;31(8):1464-9
pubmed: 22552047
J Gerontol A Biol Sci Med Sci. 2013 Jan;68(1):56-61
pubmed: 22562961
Stat Med. 2013 Feb 20;32(4):556-77
pubmed: 22711416
Prostate Cancer Prostatic Dis. 2013 Mar;16(1):91-4
pubmed: 23032361
Am J Med Genet A. 2013 May;161A(5):1064-72
pubmed: 23610051
Eur Urol. 2014 Jan;65(1):124-37
pubmed: 24207135
Int J Behav Med. 2015 Jun;22(3):283-91
pubmed: 24852184
Am J Mens Health. 2015 Sep;9(5):385-96
pubmed: 25117538
J Health Commun. 2014;19 Suppl 2:205-24
pubmed: 25315594
Am J Hum Genet. 2015 Jan 8;96(1):37-53
pubmed: 25529636
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
PLoS One. 2015 Jun 25;10(6):e0131712
pubmed: 26110842
Public Underst Sci. 2016 Jan;25(1):2-16
pubmed: 26445860
Int J Cancer. 2016 Mar 15;138(6):1388-400
pubmed: 26488767
J Cancer Educ. 2016 Dec;31(4):693-701
pubmed: 26498649
J Community Health. 2016 Aug;41(4):772-9
pubmed: 26831485
Actas Urol Esp. 2016 Jul-Aug;40(6):378-85
pubmed: 26923032
BMC Urol. 2016 May 10;16(1):19
pubmed: 27165293
Urol Oncol. 2016 Sep;34(9):415.e13-9
pubmed: 27178729
BJU Int. 2017 Jul;120(1):61-68
pubmed: 27743489
Sci Rep. 2016 Oct 17;6:35364
pubmed: 27748407
Int J Drug Policy. 2017 Jan;39:92-98
pubmed: 27780116
Front Public Health. 2017 Jan 03;4:286
pubmed: 28097120
Ecancermedicalscience. 2016 Nov 24;10:695
pubmed: 28101138
Am J Bioeth. 2017 Apr;17(4):70-72
pubmed: 28328379
Am J Mens Health. 2018 Jul;12(4):751-759
pubmed: 29658371
Am J Prev Med. 1998 May;14(4):245-58
pubmed: 9635069